Memantine Glenmark

Memantine Hydrochloride, the active ingredient in Memantine Glenmark, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for moderate to severe Alzheimer’s disease and is employed to treat cognitive decline associated with the condition in adult patients.

GNH USA supplies Memantine Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing EU‑sourced product that meets stringent quality and regulatory standards.

Memantine Glenmark is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and function.

Alzheimer’s disease (moderate to severe): improves cognition, global clinical status and daily functioning in affected patients.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue - Nausea - Confusion

Serious or Rare Side Effects: - Severe allergic reaction (rash, swelling, difficulty breathing) - Seizures - Hallucinations or psychosis - Rapid heart rate (tachycardia)

Memantine Glenmark should be used under medical supervision with attention to the following precautions. - Renal impairment: dose may need adjustment based on kidney function. - Hepatic disease: monitor liver enzymes periodically. - Concomitant CNS disorders: use cautiously in patients with epilepsy or severe psychiatric conditions. - Pregnancy and lactation: avoid unless clearly needed; discuss risks with a healthcare professional. - Elderly patients: start at low dose and titrate slowly to reduce adverse events. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Memantine Glenmark may interact with other medicines; monitoring is advised.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase risk of dizziness and confusion. - Memantine with high-dose ketamine: may potentiate neuropsychiatric effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents (e.g., diphenhydramine): may worsen cognitive side effects. - CNS depressants (e.g., benzodiazepines): may increase sedation. - Diuretics (e.g., furosemide): monitor electrolyte balance and renal function.